Remdesivir drug trials show patients recovering from COVID-19 | May 1, 2020 | Palo Alto Weekly | Palo Alto Online |

Palo Alto Weekly

News - May 1, 2020

Remdesivir drug trials show patients recovering from COVID-19

Preliminary results from Gilead Sciences, federal drug studies appear promising

by Sue Dremann

Patients are recovering from COVID-19 when they are given the experimental drug remdesivir, according to separate studies by the Foster City company that makes the drug and the National Institute of Allergy and Infectious Diseases (NIAID).

This story contains 691 words.

Stories older than 90 days are available only to subscribing members. Please help sustain quality local journalism by becoming a subscribing member today.

If you are already a member, please log in so you can continue to enjoy unlimited access to stories and archives. Membership starts at $12 per month and may be cancelled at any time.

Log in     Join

Staff Writer Sue Dremann can be emailed at [email protected]


Posted by pearl
a resident of another community
on Apr 30, 2020 at 1:54 pm

Read below about the drug remdesivir, manufactured by Gilead Sciences of Foster City, California. Gilead Sciences, Inc., is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
(Web Link)

Participants treated with remdesivir recovered from the ravages of the COVID-19 virus on average 30 percent quicker than those receiving a placebo. Even Dr. Fauci is talking about it!

Who owns remdesivir, how much can they make, and how much does it cost?
The drug was originally developed for Ebola but has shown promise with COVID-19. Web Link

Don't miss out on the discussion!
Sign up to be notified of new comments on this topic.


Post a comment

Sorry, but further commenting on this topic has been closed.

Stay informed.

Get the day's top headlines from Palo Alto Online sent to your inbox in the Express newsletter.